Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Amy Pate Patterson · CLINICAL CENTER · 2023 — Regarding our research in lipid metabolism, we have demonstrated that SR-BI mediates LDL binding as well as cholesterol ester (CE) and triacylglycerol (TAG) sorting followed by their internalization to LDs. While about 60% of LDL- delivered neutral lipid (NL) to be uploaded to LDs requires neutral h…
T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $2,198,134 — Therapy for hepatitis C virus (HCV) infection has advanced rapidly with the recent approval of several direct-acting antivirals. However, most of the DAAs in clinical use or clinical trials target the same stage of HCV replication cycle and are associated with rapid emergence of drug-resistant viral…
Niraj Tolia · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $291,366 — SARS-CoV-2 is a serious global threat that has been met with an unparalleled research response. Scientific understanding of SARS-CoV-2 is already deeper than most pathogens and it is growing rapidly. This knowledge provides an opportunity to design a vaccine that goes beyond traditional methods. …
Thomas Nutman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $166,866 — In response to the SARS-CoV-2 pandemic, we leveraged our expertise in human T cell cloning to generate SARS-CoV2-specificT cell lines from naive CD4+ and CD8+ T cells of uninfected (SARS Cov2-naive) individuals. To this end, we generated S-specific, M-specific, CMV-specific (controls), CEF-specific …
Chen-Hsiang Shen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $157,845 — An understanding of the serum responses of virus-infected individuals and vaccinees is critical for the development of effective vaccines against HIV-1, SARS-CoV-2 and other viral pathogens. Perhaps the most important biological aspect of a serum response is its neutralizing activity, with a close s…
Cheng Cheng · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,325,099 — During the past year, we have created and tested new vaccine candidates, including envelope proteins and fusion peptides displayed carrier as protein immunogens or mRNA vaccines. In addition, we have continued our work testing different methods and routes of administration as well as prime/boost com…
Aleksandra Nita-Lazar · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $99,917 — The focus of the proteomic approach is to identify and quantify viral structural proteins, specifically spike (S) glycoprotein as well as envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein in patient samples. The S protein mediates attachment of the virus to the host cell surfa…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,955,452 — We are developing parainfluenza virus- and pneumovirus-vectored vaccines for intranasal immunization against SARS-CoV-2. These viral vectors are designed to be highly attenuated in humans. They replicate to low levels in the superficial layers of the respiratory epithelium, and are optimized to indu…
Wing Pui Kong · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,480,852 — The Virology Core has collaborated with other intramural NIAID labs help to develop a pan-coronaviruses spike protein subunit vaccine and a re-emerging infectious diseases, EV-D68. During the past year, we focused on developing the vaccine vaccines against most subecoviruses or beta-coronaviruses…
Sanghyun Lee · BROWN UNIVERSITY · 2023 · $168,651 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of …
ALLAN I LEVEY · EMORY UNIVERSITY · 2023 · $848,837 — The Open Drug Discovery Center for AD (Open-AD) Structural Biology core aims to provide Target Enabling Packages (TEPs): a combination of experimental tools and knowledge that will allow researchers to investigate the biology of potential drug targets and to test therapeutic hypotheses. The TEPs wil…
Pamela J Bjorkman · ROCKEFELLER UNIVERSITY · 2023 · $971,500 — Project 3: Summary/Abstract SARS-CoV-2, a newly-emergent betacoronavirus in the sarbecovirus genus, resulted in a global pandemic in 2020, infecting millions and causing COVID-19 disease. Two other zoonotic betacoronaviruses, SARS-CoV (a sarbecovirus) and MERS-CoV (a merbecovirus), also resulted in …
David Scott Wilson · JOHNS HOPKINS UNIVERSITY · 2023 · $245,625 — 1. ABSTRACT/SUMMARY Given that the site of entry of SARS-CoV-2 is the respiratory mucosa, an effective vaccine for SARS-CoV-2 should initiate both humoral and respiratory mucosal immune responses. Although an intranasal subunit vaccine would be an ideal platform for SARS-CoV-2, transport across the …
MICHAEL G ROSENFELD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $400,697 — ABSTRACT Alzheimer’s disease (AD) presents a formidable therapeutic challenge, as current interventions have failed to slow disease progression. The majority of AD genetic risk variants identified by GWAS reside in non- coding regions of the genome, suggesting that alterations in gene expression con…
DUXIN SUN · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2023 · $513,210 — Various nanoparticles (NPs) have been used for delivery of small antigens, which have limited viral mimic features and are more efficacious than soluble antigens in stimulating B-cell immunity. However, these traditional NPs lack characteristics of virus “spiky capsid protein peplomer”, e.g. spiky a…
Jose Maria Martinez-Navio · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2023 · $785,297 — Project Summary/Abstract The poor immunogenicity of the HIV envelope spike and its vast variability represent major obstacles for efficient elicitation of protective anti-HIV antibodies. One promising strategy is to bypass the immune system and deliver already known and well-characterized potent and…
MARK ROBERTS LOONEY · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $623,280 — Project Summary/Abstract The acute respiratory distress syndrome (ARDS) was first formally described in 1967, but it has likely been the predominant cause of death in pandemic viral infections for centuries. Now, the world is at grips with a new pandemic from SARS-CoV-2, or COVID-19, which has infec…
Nicola Decaro · OHIO STATE UNIVERSITY · 2023 · $205,587 — 1 Project Summary 2 There is growing evidence that canine coronaviruses (CCoVs) can infect humans and be associated with 3 clinical (mostly acute respiratory) illness in children and adults. Human infections with CCoVs with recombinant 4 canine-feline-porcine spike proteins (hCFPL-CoVs) have been…
Gillian Fitz · VANDERBILT UNIVERSITY · 2023 · $30,666 — PROJECT SUMMARY/ABSTRACT In Eukarya, actin-based protrusions such as filopodia, stereocilia, and microvilli, support a wide variety of cellular functions including motility, mechanosensation, and nutrient absorption. Formation of a surface protrusion involves deformation of the plasma membrane, and…
WALTHER H MOTHES · YALE UNIVERSITY · 2023 · $825,206 — Summary The COVID19 pandemic may take 1-3 years and only fully subside once we reach herd immunity. Given the high mortality of COVID19, it is of critical importance to reach herd immunity through a vaccine. The viral spike glycoprotein (S) is central to our efforts for developing an effective vacci…